Ligand id: 7385

Name: catumaxomab

No information available.
Summary of Clinical Use
Approved to treat cancer-associated peritoneal ascites fluid accumulation in patients with EpCAM +ve cancers. The EMA has also granted this drug orphan designation for the treatment of gastric cancer.
Mechanism Of Action and Pharmacodynamic Effects
Catumaxomab acts by binding to epitopes on malignant cells (EpCAM), T cells (CD3e) and antigen-presenting cells (Fc receptor on macrophages, natural killer cells or a dendritic cells), and thus directs the immune system to selectively destroy the malignant cells . Reducing the number of cancer cells, reduces the abdominal build up of ascites fluid.
External links